New shot could tame stubborn high cholesterol
NCT ID NCT07421297
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new injectable drug called SYH2053 in 760 adults with high cholesterol or mixed lipid disorders. Participants receive either the drug or a placebo to see if it safely lowers LDL ('bad') cholesterol. The study aims to offer a new treatment option for people who haven't met their cholesterol goals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYH2053 injection
What this could lead to
If it works, this could provide a new injectable option to help control high cholesterol and reduce heart disease risk.
What could go wrong
This is a Phase 3 trial, but results may not show a meaningful benefit over existing treatments. Side effects or lack of long-term safety data could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-FAMILIAL HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliation: Peking University Third Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Affiliation: Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••